FCGR2B and in situ carcinoma: Three previous studies of people with CIS or remitting relapsing MS (RRMS) had demonstrated no difference in expression of mRNA of the gene encoding CD32b in total leukocytes or CD32b expression on B cells from people with MS compared with healthy individuals (50–52).